Developing new treatments to combat bacterial resistance using biopharmaceuticals
Preclinical Services for Antibacterial Resistance Biopharmaceutical Product Development
This study is working on new treatments to help fight infections caused by bacteria that are hard to treat, using special tools like antibodies and RNA, and it's designed for anyone interested in better options for managing these tough infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International AIDS Vaccine Initiative NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10934766 on NIH RePORTER |
What this research studies
This research focuses on the preclinical development of innovative biopharmaceutical products aimed at addressing bacterial drug resistance. It involves creating and evaluating various biological materials, including monoclonal antibodies and small interfering RNA (siRNA) vectors, to enhance treatment options for infectious diseases. The program provides comprehensive services such as product development planning, assay development, and regulatory support to ensure effective translation of these therapies into clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with infections that are resistant to current antibiotic treatments.
Not a fit: Patients with infections that are not caused by bacterial pathogens or those who do not have drug-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for patients suffering from infections caused by drug-resistant bacteria.
How similar studies have performed: Other research in the field of biopharmaceuticals and antibacterial resistance has shown promise, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- International AIDS Vaccine Initiative — New York, United States (Active)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.